Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical

被引：0
|
作者：
West, H. J.
Belt, R. J.
Wakelee, H. A.
Monberg, M. J.
Frye, L. A.
Ye, Z.
Obasaju, C. K.
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] Kansas City Canc Ctr, Kansas City, MO USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：393S / 393S
页数：1
相关论文
共 50 条
  • [41] Phase II study of sunitinib malate (SU) as consolidation therapy in patients (pts) with locally-advanced or metastatic non-small cell lung cancer (NSCLC)
    Gervais, R.
    Hainsworth, J. D.
    Blais, N.
    Soria, J. C.
    Laskin, J.
    Hamm, J. T.
    Lipton, A.
    Tye, L.
    Chao, R.
    Page, R. D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 372 - 372
  • [42] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [43] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Barata, F.
    Parente, B.
    Teixeira, E.
    Costa, A.
    Fernandes, A.
    Pimentel, F. L.
    Carvalho, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)-Final report
    Sovak, M. A.
    Guensch, L.
    Joyce, P.
    Lutzker, S. G.
    Schwartz, S.
    Shih, W. J.
    Zheng, L.
    Aisner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Phase II study of weekly docetaxel and gemcitabine in relapsed patients (pts) with advanced, platinum-exposed non-small cell lung cancer (NSCLC)
    Langer, C. J.
    Huang, C.
    Ruth, K.
    Shafer, D.
    Borghaei, H.
    Millenson, M.
    Mintzer, D.
    Staddon, A.
    Seldomridge, J.
    Tuttle, H.
    Treat, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Phase II study of Gemcitabine, ifosfamide and cisplatin (GIP) in patients with advanced non-small cell lung cancer (NSCLC)
    De las Penas, R
    Busquier, I
    Munarriz, J
    Lopez, A
    Llorente, R
    Alberola, V
    Frau, A
    ANNALS OF ONCOLOGY, 1998, 9 : 88 - 88
  • [47] Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC).
    Hoang, T
    Kim, K
    Merchant, J
    Traynor, AM
    Ahuja, HG
    Masters, GA
    McGovern, JD
    Oettel, KR
    Sanchez, FA
    Schiller, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 642S - 642S
  • [48] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [49] Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer
    Monnerat, C
    Le Chevalier, T
    Kelly, K
    Obasaju, CK
    Brahmer, J
    Novello, S
    Nakamura, T
    Liepa, AM
    Bozec, L
    Bunn, PA
    Ettinger, DS
    CLINICAL CANCER RESEARCH, 2004, 10 (16) : 5439 - 5446
  • [50] Phase II trial of gemcitabine (G), carboplatin (C) and bexarotene (B) in patients (pts) with newly diagnosed, locally-advanced or metastatic non-small cell carcinoma of the lung (NSCLC).
    Estephan, FF
    Hasham-Jiwa, N
    Klementich, F
    Logrono, R
    Eltorky, M
    Bhutani, M
    Walser, E
    Zwischenberger, J
    Kessel, I
    Jones, DV
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 697S - 697S
12345